Coiled Coil Domain Containing 6 gene, CCDC6, was initially isolated as part of a tumorigenic DNA originated by the fusion of CCDC6 with the tyrosine kinase of RET receptor, following a paracentric inversion of chromosome 10. For a long time, CCDC6 has been considered as an accidental partner of the RET protooncogene, providing the promoter and the first 101 aa necessary for the constitutive activation of the oncogenic Tyrosine Kinase (TK) RET in thyroid cells. With the advent of more refined diagnostic tools and bioinformatic algorithms, an exponential growth in fusion genes discoveries has allowed the identification of CCDC6 as partner of genes other than RET in different tumor types. CCDC6 gene product has a proper role in sustaining the DNA damage checkpoints in response to DNA damage. The inactivation of CCDC6 secondary to chromosomal rearrangements or gene mutations could enhance tumor progression by impairing the apoptotic response upon the DNA damage exposure, contributing to the generation of radio-and chemoresistance. Preclinical studies indicate that the attenuation of CCDC6 in cancer, while conferring a resistance to cisplatinum, sensitizes the cancer cells to the small molecule inhibitors of Poly (ADP-ribose) polymerase (PARP1/2) with a synthetic lethal effect. Several CCDC6 mutations and gene rearrangements have been described so far in different types of cancer and CCDC6 may represent a possible predictive biomarker of tumor resistance to the conventional anticancer treatments. Nevertheless, the detection of a CCDC6 impairment in cancer patients may help to select, in future clinical trials, those patients who could benefit of PARP-inhibitors treatment alone or in combination with other treatments.
Background

CCDC6 isolation
Coiled Coil Domain Containing 6 gene, CCDC6, was initially isolated as part of a tumorigenic DNA obtained from a papillary thyroid carcinoma, upon transfection in mouse NIH3T3 cells in an in vitro cell transforming assay. [1] [2] [3] The isolated gene emerged to derive from the fusion of two genes: one, known as the tyrosine kinase receptor RET and the other as an unknown DNA sequence at the 5 0 . The partner sequence fused to RET turned out to be the CCDC6 gene, initially named H4(D10S170). The CCDC6 gene sequence was mapping on the right arm of chromosome 10 in position S170. The rearrangement of the two genes, CCDC6 and RET, derived from a paracentric inversion of the right arm of chromosome 10 (10 < inv (10)(qll. 2q21)>), leading to the chimeric oncogene PTC1, from Papillary Thyroid Carcinoma. 4 For a long time, CCDC6 was considered as an accidental partner of the RET protooncogene, providing the promoter and the first 101 aa necessary for the constitutive activation of the Tyrosine Kinase (TK) domain of RET, localized at carboxy-terminus.
This conviction became stronger when other heterologous partners were discovered and found fused to the promiscuous RET kinase upon different chromosomal rearrangements. [5] [6] [7] Actually, the common figures of the partner genes fused to RET are: a promoter driving the ectopic expression of the kinase, and a protein domain providing the surface for the dimerization and constitutive activation of the truncated TK receptor. 8 Soon after the isolation of the recombinant oncogenes, it became clear that each partner gene, included CCDC6, was determining a change in the intracellular localization of the kinase with the activation of an ectopic signaling, as suggested by the data of the differential gene expression profile. [9] [10] [11] [12] Thus, different biological effects induced by the partners in fusion lead to different clinical outcomes with different possibility to be effectively targeted for therapy. [13] [14] [15] [16] [17] [18] [19] [20] If the CCDC6 partner gene was partnering exclusively with RET, and if its partnering was restricted to thyroid cells remained unsolved for several years. As matter of fact, the involvement of CCDC6 in its fusion with RET occurred in about 20% of human thyroid papillary carcinomas and appeared to be associated with the exposure to ionizing radiation. [21] [22] [23] [24] [25] [26] [27] The high frequency of CCDC6/RET rearrangement in thyroid cells was related to the spatial contiguity of the loci of the two genes in the nucleus of thyroid cells. Furthermore, the two loci were identified, by in vitro experiments, as hot spots of recombination upon exposure to ionizing radiation (IR). 23 However, in transgenic mice carrying CCDC6/RET fusion, the occurrence of tumors other than thyroid suggested a more general role of CCDC6/RET fusion in tumor induction, independent of the thyroid context. 28 Accordingly, in the last few years, CCDC6/RET fusion has been reported in tumor types different from thyroid, such as the human lung adenocarcinoma and the colorectal carcinoma (Fig. 1) . [29] [30] [31] [32] [33] [34] With the advent of more refined diagnostic tools and bioinformatic algorithms, an exponential growth in fusion genes discoveries has allowed the identification of CCDC6 as partner of genes other than RET in different tumor types ( Fig. 1 ; Table 1 ). [35] [36] [37] [38] [39] [40] These findings clearly indicate that CCDC6 gene has a high susceptibility for recombination. Possibly, the list of the recombinant proteins involving CCDC6 will grow in the next few years. 35, 41 The side contribution of the partner genes in cell transformation has been demonstrated in several cases of chimeric genes. Multiple partner genes in fusions contribute functionally to the activity of the known oncogene like MYC, MLL, RARA, ALK and RUNX1. [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] Most of the genes fused to CCDC6, identified so far, are well known oncogenes that promotes the enhancement of cell proliferation. The simultaneous loss or inactivation of CCDC6 contributes to the oncogenic activity by affecting the DNA damage repair and reducing the apoptotic surveillance. Therefore, it is possible that the transforming potential of CCDC6/RET is not limited to the RET tyrosine kinase activation, and CCDC6 might provide a weighty contribution to cancer development and progression.
CCDC6 structure and functions
The cDNA corresponding to the sequence of the gene, initially identified as H4(D10S170), was isolated from a human normal thyroid cDNA library and sequenced. The CCDC6 3 kb transcript (4401 bp) is highly conserved in the phylogeny and is expressed in almost all human tissues. 53 The CCDC6 transcript contains an open reading frame (ORF) of 475 amino acids with a start site that is localized to a region 2100 to 2190 (-144) bp of the translation initiation site (ATG). The CCDC6 promoter is located to a region within 259 bp upstream of the ATG site. 53, 54 From the biochemical point of view, the 65 kDa product of CCDC6 has a nuclear transfer sequence with no transmembrane domains and is predicted to locate in both the nucleus and the cytoplasm (Fig. 1) . The CCDC6 protein is detected in the nucleus and the cytoplasm of the analyzed cells. 55 A putative SH3 binding site, at the carboxy-terminus, provides an adaptor domain for regulatory mechanisms. 54 Overall, CCDC6 protein has a main structure of coiled coil domains that allows protein-protein interactions; this main structure inspired the name for the gene, Coiled Coil Domain Containing 6 (CCDC6).
53-56
The CCDC6 is a phosphoprotein, predicted target of several S/T kinases which can modulate the protein stability and the intracellular shuttling into the nucleus upon different cellular signals mediated by ERK1/2, ATM and CDK1/2 ( Fig.  2) . 55, [57] [58] [59] Following the exposure to genotoxic stress the activated ATM kinase induces phosphorylation of CCDC6 at threonine 434 determining the nuclear stabilization of the protein. Indeed, in ATM defective cells (A-T cells) the endogenous CCDC6 is localized in the cytoplasm and is excluded from the nucleus. Interestingly, CCDC6 is not phosphorylated after ionizing radiations in ATM-deficient lymphoblasts and in ATM proficient cells the inhibition of ATM kinase interferes with CCDC6 apoptotic activity. Additionally, the expression of a mutant CCDC6 protein, containing an alanine at threonine 434, excludes the CCDC6 protein from the nucleus and protects the cells from apoptosis induced by genotoxic stress. 58 Thus, CCDC6 is involved in cellular response to DNA damage mediated by ATM, with the final result of promoting cellular apoptosis.
Mammalian cells silenced for CCDC6 survive better to IR exposure in clonogenic assay, and progress into mitosis upon the DNA damage. 60 Cells lacking CCDC6 do not show Sphase accumulation upon exposure to etoposide. 61 In the absence of CCDC6 and in the presence of genotoxic stress (etoposide or irradiation) cells repair the induced damage by nonhomologous-end-joining (NHEJ) that is prone to errors in DNA sequence. Low levels of CCDC6 protein are associated with low number of Rad51 repairing foci and a weak response to DNA damage. 60 Therefore, CCDC6 depleted cells are considered defective of DNA repair checkpoint and proceed faster than the control cells in the cell cycle upon induced DNA damage. The molecular mechanism that has been postulated for this biological effect describes CCDC6 as negative regulator of the Serin-Threonin Protein Phosphatase 4, PP4c, that dephosphorilates H2AX on S139 (gH2AX), unlabeling the DNA repairing process (Fig. 2) . Loss or inactivation of CCDC6 releases the activity of PP4c, that dephosphorylates gH2AX, resulting in a reduction of DDR foci. Eventually, the reduction of DDR foci overcomes the G2 arrest, which is required for the complete and correct repair of the damaged DNA. Interestingly, the phosphorylation of CHK1 protein, that represents a sign of activated cellular checkpoint upon DNA damage, is not detectable when CCDC6 is absent. 60 Moreover, the cytoplasmic sequestration of the S-phase checkpoint CDC25C phosphatase, that is induced upon genotoxic stress, does not occur if CCDC6 is depleted. 61 Regardless of induced genotoxic stress, cells lacking CCDC6 show a down-regulation of 14-3-3r, a major cell cycle regulator. The down-regulation of 14-3-3r in absence of CCDC6 supports the notion that CCDC6 contributes to cancer development, possibly through malignant pathways involved in cell cycle regulation. 62 Moreover, the down regulation of the tumor suppressor EWS transcript promotes cellular apoptosis in a CCDC6-dependent manner. 63 Interestingly, CCDC6 protein levels fluctuate in dependence of cell cycle phases and upon stress induction. CCDC6 undergoes a cyclic variation in the phosphorylated status and in protein levels that peak at G2 and decrease in mitosis (Fig.  2) . 59, 63, 64 The intracellular amount of CCDC6 protein is regulated by post-transcriptional modifications rather than by transcription. 59, 65, 66 The reduced stability of CCDC6 in the M phase is dependent on mitotic kinases and on degron motifs that are present in CCDC6 and direct the recruitment of the CCDC6 E3 Ubiquitin ligase. FBXW7 E3 ubiquitin ligase interacts with CCDC6 and targets CCDC6 for ubiquitinmediated proteasomal degradation (Fig. 2) . Upon DNA damage, FBXW7-mediated CCDC6 degradation is impaired. Mechanistically, phosphorylation of CCDC6 at Thr434 by ATM during DNA damage response prevents FBXW7-CCDC6 interaction and FBXW7-mediated CCDC6 degradation. 65 Moreover, CCDC6 is target of USP7 deubiquitinase and its levels in turn depend on FBXW7 and USP7 activity (Fig. 3) . 59 Thus, CCDC6 is a fine tuned protein that operates in response to DNA damage altering the cellular checkpoints of DNA damage recovering.
A mass-spec analysis indicated that CCDC6 protein interacts directly with several proteins which can form complex with DNA. Some of CCDC6 interactors also act as regulators of transcription. CCDC6 binds to the transcription factor CREB1, which is known to regulate transcription of proteins involved in cell proliferation (Fig. 2) .
67 CCDC6 represses CREB1 transcriptional activity, in a SUMO2 regulated manner, by recruiting histone deacetylase 1 and protein phosphatase 1 (PP1) at the CRE site of the CREB1 target genes (Fig. 3) . 66, 67 Based on computational analysis, some proteins involved in the DSBs DNA repair by homologous recombination (HR), such as BRCC3 and BAP1, of the BRCA1 complex have been predicted to interact with CCDC6 and are in need of further investigations. 68 Figure 2. CCDC6 activity in cell cycle. Diagram of CCDC6 protein modifications occurring during cell cycle phases. In the wheel are reported the main CCDC6 protein-protein interactions in S/G2 phases following DNA damage exposure. CCDC6 degradation upon ubiquitination by FBXW7 occurs just before the cell entrance in mitosis. Following genotoxic stress, ATM activation induces CCDC6 phosphorylation and stabilization in the nucleus where it interacts with the catalytic subunit of the PP4C phosphatase and inhibits the phosphatase activity on the phosphorylated S139 residue of the histone H2AX. Because of CCDC6, H2AX is maintained in a phosphorylated status in the repair foci; the cell cycle is delayed until the resolution of the DNA double strand breaks (DSBs). Then, CCDC6 is degraded. [Color figure can be viewed at wileyonlinelibrary.com]
In particular, BRCC3 encodes a subunit of the BRCA1-BRCA2-containing complex (BRCC). This complex plays a role in the DNA damage response, where it is accountable for the stable accumulation of BRCA1 at DNA break sites. The component encoded by this gene can specifically cleave Lys 63-linked polyubiquitin chains, removing Lys-63-linked ubiquitin on histones H2A and H2AX. 69 Thus, it can be postulated that CCDC6 could be able to control the H2AX phosphorylation status through PP4c, and the H2AX stability through BRCC3, in response to genotoxic stress. In the future, experiments of Chromatin IP and ChIP on chip analysis, performed in different conditions, will possibly identify the protein complexes and define the transient nuclear interactions in which CCDC6 takes part, clarifying its role in transcription and DNA repair.
Overall, the existing evidence indicates that CCDC6 plays a proper role in maintenance of genomic stability, cell cycle control and cell survival. These evidences provide a rational of how the impairment of CCDC6 function may contribute to malignancy.
CCDC6 defect in cancer: models of tumor suppression
In vitro assays indicate that CCDC6 coiled coil domains provide the hydrophobic surface for CCDC6 oligomerization. 70, 71 The 101 aa of CCDC6 domain included in the fusiononcoproteins, like in PTC1, acts as dominant negative of the nuclear localization of the endogenous full length protein CCDC6, expressed by the residual wild type allele. 55 This effect could promote cancer beside determining the homo-dimerization and transforming ability of the fusiononcoprotein. Accordingly, Ccdc6-ex2 knock-in mice developed thyroid hyperplasia associated with an enhanced CREB1 activity and an increased expression of the CREB-1 regulated genes. 67, 72 These evidences strongly support a proper role of CCDC6 impairment in promoting the tumor development. Until now, limited investigations have been performed on RET/CCDC6, the product derived from the reciprocal of the fusion and in which CCDC6 is situated at the 3 0 of the reciprocal gene rearrangement. Recently, few exceptions to the mentioned fusions have been reported, such as the FGFR2/CCDC6 rearrangement, where the CCDC6 gene contributes the coiled coil region at the 3 0 of the chimeric oncogene. 73, 74 In these cases, the role of CCDC6 in the activation of the oncogene is unclear, but we can hypothesize that the folding of the fusion protein may allow, through the coiled coil region, the dimerization of the protein and the oncogene activation. Moreover, the reciprocal fusion, if expressed, could act in a dominant negative way versus the wild-type allele. Nevertheless, the mechanisms of CCDC6 contribution, hypothesized above, still require further analysis.
The abolishment of CCDC6 expression or its nuclear exclusion associate with cancer. 75 A weak CCDC6 protein staining in IHC analysis has been significatively correlated with the presence of lymph node metastasis (p 0.02) and negatively correlated with the disease free survival (p 0.01) and the overall survival (p 0.05) in NSCLC patients (Table  1) . 76, 77 More recently, lung cancer patients who developed resistance to EGFR tyrosine kinase inhibitors (TKi), have shown the activation of CCDC6-RET in post progression samples. 78 Interestingly, beside of being partner of fusion proteins, CCDC6 has been found mutated in different tumor types (substitutions nonsense 11.25%, missense 61.25%, synonymous 13.75%, inser/del inframe 7,75%,inser/del frameshift 3.75%), (Table1), http://cancer.sanger.ac.uk/cosmic/ search?q5CCDC6. Besides the nonsense mutations, which could lead to dominant negative isoforms of CCDC6, the missense mutations, identified so far in different cancer types, are distributed along the whole sequence of the CCDC6 protein, with no clustering in specific protein domains. Moreover, no specific correlation with cancer types has been found. Finally, none of the CCDC6 point mutations have been explored in tumors carrying the CCDC6 fusions, neither the additive role of fusion and mutations have been investigated in in vitro cancer cell systems. Thus, we believe that each of the identified missense mutations deserves a functional characterization, that will be the object of our analysis in the next future.
To date, a systematic study to classify CCDC6 gene mutations or rearrangements in primary tumors is still missing, while a wide IHC analysis to group different cancer types for cellular localization and nuclear exclusion of CCDC6 is now in progress (Merolla et al. in preparation) .
In the future, we expect that the detection of CCDC6 nuclear exclusion by IHC could possibly contribute to disclose those cases in which the analysis of CCDC6 rearrangements or mutations cannot be explored as first assessment.
Therapeutic implication of CCDC6 impairment in cancer: new strategies of combined treatments to avoid drug resistance. Identification of fusion genes and their specific contribution in malignancy are crucial for understanding the molecular pathogenesis and clinical phenotype of cancer, to determine prognostic indexes and therapeutic responses, and to monitor residual disease and relapse status.
The prominent role of CCDC6 in the DNA damage could influence genome stability in primary tumors. Cells defective for CCDC6 perform as BRCA-like defective cells, with resistance to chemotherapeutic agents and sensitivity to small molecule inhibitors of the repair enzymes PARP1/2 (Fig.  3) . 76, 77, 79, 80 The inhibition of PARP enzymes as anticancer strategy has been established on the basis of the biological concept of synthetic lethality with BRCA defect. 81 When PARP enzymes are pharmacologically inhibited, the DNA single strand breaks cannot be repaired and eventually progress to toxic double strand breaks (DSBs), which result to be lethal in cells that lack HR repair capacity or have lost DNA repair genes. 81, 82 Low levels of CCDC6 associate with an impairment of HR mechanisms, affecting cells behavior and cells sensitivity to PARP inhibitors (PARPi) treatment in lung and colon cancer models. 59, 76 In accordance with CCDC6 role in the DNA damage response, CCDC6 attenuation in lung cancer cells confers resistance to cisplatinum and sensitizes the cells to the PARPi olaparib. Remarkably, the combination of the PARPi with the conventional chemotherapy is more effective than each agent individually. 59, 76, 77, 79, 80 On these bases, CCDC6 could be envisaged as a predictive biomarker of resistance to conventional single mode therapy and yields insight to tumor sensitivity to PARPi in NSCLC.
Similarly, CCDC6 attenuation in prostate cancer cells confers sensitivity to olaparib, independently on their status of castration resistance. 80 Almost 30% of patients with Castration Resistant Prostate Cancer, CRPC, carry DNA repair gene mutations with a high possibility to respond to PARPi treatment. 83, 84 The identification of CCDC6 as a possible predictive biomarker of tumor sensitivity to PARPi in CRPC will increase the number of CRPC patients that could benefit of PARPi treatment.
Thus, the biological data generated on CCDC6 in the last 10 years need to be transferred to the clinic in order to evaluate the predictive role of defective CCDC6 for the efficacy of PARPi, like performed in the case of BRCA1/2, ATM, CHEK2, Fanconi's Anemia and other genes involved in DNA repair. 81, 82 Tumors carrying the CCDC6-RET oncogene or occurring in Ccdc6-ex2 knock-in mice show an increased phosphorylation and activity of CREB1 which leads to the expression of Amphiregulin, AREG, one of the ligands for the EGFR family. 67, 72, 85 If this molecular mechanism will turn out to be important for cancer cell proliferation, the absence of CCDC6 will also have relevant therapeutic implications for the targeting of the EGFR family members in selected tumors. 86, 87 The activation of epidermal growth factor (EGF) is known to trigger resistance to RET inhibitors, bypassing survival signaling through ERK and AKT activation. Targeting EGFR using specific TKi like gefitinib restores cancer cells sensitivity to RET inhibitors. 85 Interestingly, the sensitivity to RET inhibitors in CCDC6-RET lung cancer cells is increased when EGF signaling is inhibited by EGFR small interfering RNA (siRNA), anti-EGFR antibody (cetuximab), and EGFR-TKi (Iressa). 88 If a role can be ascribed to CCDC6 in the activation of the EGFR signaling, the detection of CCDC6 impairment could represent an indication for targeting EGFR in cancer therapy (Morra et al. manuscript in preparation).
Interestingly, the activation of CCDC6-RET has been identified in postprogression samples of lung cancer patients which developed resistance to EGFR TKi. 78 Thus, the inactivation of CCDC6 in combination with the activation of RET could be recognized as an alternative mechanism of EGFR TKi resistance, beside the EGFR T790M mutation, EGFR amplification, HER2 amplification, MET amplification, PIK3CA mutation and BRAF mutation. 89, 90 On these bases, TKi that show off targets effects might result to be more effective in those cases in which RET TK activation is combined with the enhancement of EGFR signaling because of the CCDC6 impairment.
Off targets effects of TKi could be considered a better therapeutic option in thyroid or lung tumors that carry CCDC6/RET fusion protein as well as in breast cancer and in iCCA that carries FGFR2-CCDC6 fusion protein in order to avoid tumor progression and TKi resistance. 73, 74 If the mechanism of stabilization and degradation of the CCDC6 gene product is dependent on a cross talk between ubiquitinase and deubiquitinase activity, their targeting should also affect CCDC6 behavior in response to genotoxic stress. The targeting of USP7 to reduce CCDC6 levels appears to be useful for the establishment of new therapeutic approaches in cancer treatment. The pharmacological inhibition of USP7 leads to downregulation of CCDC6 protein and results in DNA repair defect that sensitizes cancer cells to PARP inhibitor treatment, alone or in combination with standard radio-and chemotherapies (Fig. 3) . Combined effects of the inhibitors of USP7 and PARP enzymes have been reported in the treatment of SCLC expressing USP7 and CCDC6 proteins. 79 Moreover, the inhibition of USP7 enzyme, in combination with the PARP inhibitors, could represent an ideal treatment in both hormone-sensitive and androgen-resistant prostate tumors that express both USP7 and CCDC6.
80
USP7 has different substrates beside CCDC6, including AR and PTEN. 91, 92 Previous literature had suggested radiosensitization from PARP inhibition in prostate cancer cells with DNA repair defects, accordingly to the concept of "native synthetic lethality." 81, 82, 91 The downregulation of the USP7 substrates, such as CCDC6, AR and PTEN, obtained with the inhibition of their de-ubiquitinating enzyme USP7 may lead as well to an "induced synthetic lethality" when combined with PARP inhibition (Fig. 3) . 80 
Conclusions
CCDC6 is impaired in different types of cancer because of somatic mutations and reduced expression, beside the growing number of chromosomal rearrangements in which has been involved so far. The alterations of CCDC6 identified in cancer indicate that CCDC6 gene, beside the high susceptibility for recombination, provides a proper contribution to cancer development and progression. In normal cells CCDC6 operates in response to DNA damage, controlling the cellular checkpoints of DNA damage recovering, with the final result of promoting cell cycle control and maintenance of genomic stability or alternatively leading to apoptosis. At the moment, it is necessary to perform a systematic scrutiny of CCDC6 gene mutations or rearrangements in primary tumors; as well, a wide IHC staining to group different types of cancer for the intracellular localization and/or nuclear exclusion of CCDC6 is required.
As CCDC6 defects may represent predictive biomarkers of tumor resistance to the conventional anticancer treatments, the detection of CCDC6 impairment in cancer patients may help to select, in future clinical trials, those patients who could benefit of targeted therapies alone or in combination with standard treatments.
